Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

48.70
+0.03000.06%
Volume:63.51K
Turnover:3.09M
Market Cap:2.34B
PE:-15.95
High:49.38
Open:48.17
Low:47.90
Close:48.67
52wk High:52.93
52wk Low:14.11
Shares:47.98M
Float Shares:30.39M
Volume Ratio:0.28
T/O Rate:0.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0525
EPS(LYR):-2.8633
ROE:-39.96%
ROA:-25.78%
PB:5.52
PE(LYR):-17.01

Loading ...

BTIG Reaffirms Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Jun 02

Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $743,673.08

Reuters
·
May 29

Rapport Therapeutics, Inc. (RAPP) Receives a Buy from BTIG

TIPRANKS
·
May 21

Rapport Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
May 21

Rapport Therapeutics to present at Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 21

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

GlobeNewswire
·
May 21

Rapport Therapeutics Coverage Assumed by Truist Securities at Buy

Dow Jones
·
May 20

Rapport Therapeutics assumed with a Buy at Truist

TIPRANKS
·
May 19

Third Rock Ventures V disposes 133,618 Rapport Therapeutics shares for $5.38 million

Reuters
·
May 14

Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $11,096,094.77

Reuters
·
May 12

Rapport Therapeutics Price Target Maintained With a $53.00/Share by BTIG

Dow Jones
·
May 08

Rapport Therapeutics, Inc. (RAPP) Gets a Buy from JonesTrading

TIPRANKS
·
May 08

Analyst Reiterates Buy on RAP-219 Developer as Accelerating Clinical Milestones and Multi-Indication Potential Enhance Risk‑Reward Profile

TIPRANKS
·
May 08

Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market

TIPRANKS
·
May 08

Rapport Therapeutics reports Q1 EPS (42c), consensus (71c)

TIPRANKS
·
May 07

Rapport Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 07

Rapport Therapeutics Q1 FY26 net loss narrows to $19.9 million; revenue rises to $20 million

Reuters
·
May 07

Press Release: Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

Dow Jones
·
May 07

Rapport Therapeutics announces annual shareholder meeting

Reuters
·
Apr 23

Rapport Therapeutics Price Target Maintained With a $53.00/Share by BTIG

Dow Jones
·
Apr 23